PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, Christina Barbara Walter, Eva‐Maria Grischke, Sara Yvonne Brucker
Breast Care · 2016 · 30,989 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016). PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer. Breast Care, 11(6), 385–390. https://doi.org/10.1159/000453569
In text: (Hartkopf et al., 2016)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
Related papers
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review2017
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency2015
Metadata from OpenAlex (CC0). Citations are generated from the published record.